Trav20: A Potential Drug Target for Cancer and Other Diseases

Target Name: TRAV20

NCBI ID: G28663

TRAV20

Other Name(s): TCRAV30S1 | TCRAV20S1 | T cell receptor alpha variable 20

Trav20: A Potential Drug Target for Cancer and Other Diseases

Trav20 (TCRAV30S1) is a drug target (or biomarker) that has been shown to play a crucial role in the development and progression of various diseases, including cancer. Trav20 is a small non-coding RNA molecule that has been identified as a potential drug target in the field of oncology.

Trav20 is a highly conserved gene that is found in many different organisms, including humans. It is expressed in a variety of tissues and cells throughout the body, including the brain, heart, and gastrointestinal tract. Trav20 is also known to be involved in the regulation of gene expression, which is a critical process that allows cells to create the proteins they need for proper function.

One of the key functions of Trav20 is its role in the regulation of cell adhesion. Adhesion is the process by which cells stick together and form tissues. Trav20 is involved in the regulation of cell-cell adhesion, as well as cell-tissue adhesion. This is important for the development and maintenance of tissues and organs, as well as for the formation of the immune system.

Trav20 is also known to be involved in the regulation of cell signaling pathways. Signaling pathways are the processes by which cells communicate with each other and with their environment. Trav20 is involved in the regulation of several signaling pathways, including the TGF-β pathway and the Wnt pathway. These pathways are important for the development and maintenance of tissues and organs, as well as for the regulation of growth and differentiation.

In addition to its role in cell signaling pathways, Trav20 is also known to be involved in the regulation of gene expression. Trav20 has been shown to play a role in the regulation of gene expression by binding to specific DNA sequences. This allows Trav20 to influence the activity of other genes and to control the output of cellular processes.

Trav20 is also a potential drug target because of its involvement in the regulation of cell signaling pathways and its role in the regulation of cell adhesion. This makes it an attractive target for the development of new pharmaceuticals for the treatment of various diseases, including cancer.

In conclusion, Trav20 is a drug target (or biomarker) that has the potential to be a valuable tool in the development and treatment of various diseases. Further research is needed to fully understand the role of Trav20 in cellular processes and to develop new pharmaceuticals that can effectively target this protein.

Protein Name: T Cell Receptor Alpha Variable 20

Functions: V region of the variable domain of T cell receptor (TR) alpha chain that participates in the antigen recognition (PubMed:24600447). Alpha-beta T cell receptors are antigen specific receptors which are essential to the immune response and are present on the cell surface of T lymphocytes. Recognize peptide-major histocompatibility (MH) (pMH) complexes that are displayed by antigen presenting cells (APC), a prerequisite for efficient T cell adaptive immunity against pathogens (PubMed:25493333). Binding of alpha-beta TR to pMH complex initiates TR-CD3 clustering on the cell surface and intracellular activation of LCK that phosphorylates the ITAM motifs of CD3G, CD3D, CD3E and CD247 enabling the recruitment of ZAP70. In turn ZAP70 phosphorylates LAT, which recruits numerous signaling molecules to form the LAT signalosome. The LAT signalosome propagates signal branching to three major signaling pathways, the calcium, the mitogen-activated protein kinase (MAPK) kinase and the nuclear factor NF-kappa-B (NF-kB) pathways, leading to the mobilization of transcription factors that are critical for gene expression and essential for T cell growth and differentiation (PubMed:23524462). The T cell repertoire is generated in the thymus, by V-(D)-J rearrangement. This repertoire is then shaped by intrathymic selection events to generate a peripheral T cell pool of self-MH restricted, non-autoaggressive T cells. Post-thymic interaction of alpha-beta TR with the pMH complexes shapes TR structural and functional avidity (PubMed:15040585)

The "TRAV20 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRAV20 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets